KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD

Status:
Completed

Trial end date:
2019-07-09

Target enrollment:

Participant gender:

This study is a multicenter, dose-optimized, open-label safety study with KP415 in children with Attention-Deficit/Hyperactivity Disorder (ADHD).

Phase 3

KemPharm, Inc.